Phase II Results of Ara-C and Idarubicin in Combination with the Selective Inhibitor of Nuclear Export (SINE) Compound Selinexor (KPT-330) in Patients with Relapsed or Refractory AML

被引：8
|
作者：
Fiedler, Walter [1 ]
Heuser, Michael [2 ]
Chromik, Joerg [3 ]
Thol, Felicitas [2 ]
Bokemeyer, Carsten [4 ]
Theile, Susann [5 ]
Lebkuechner, Isabell [5 ]
Kranich, Anne L. [6 ]
机构：
[1] Univ Hosp Eppendorf, Dept Hematol & Oncol, Hamburg, Germany
[2] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany
[3] Univ Hosp Frankfurt, Frankfurt, Germany
[4] Univ Med Ctr Hamburg Eppendorf, Ctr Oncol, Med Clin & Polyclin 2, Hamburg, Germany
[5] GSOmbH, Hamburg, Germany
[6] GSO Global B V, Amsterdam, Netherlands
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.341.341
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
341
引用
收藏
页数：6
相关论文
共 50 条
  • [21] A phase 1b food effect study of the first-in-class, oral, selective inhibitor of nuclear export (SINE) selinexor (KPT-330) in patients (pts) with advanced sarcomas.
    Gounder, Mrinal M.
    Loong, Herbert H. F.
    Nyquist-Schultz, Kjirsten
    Baker, Stephanie
    Ustoyev, Yelena
    Tanner, Lanier R.
    Shacham, Sharon
    McCauley, Dilara
    Rashal, Tami
    Saint-Martin, Jean-Richard
    Shacham, Eran
    Friedlander, Sharon
    Tamir, Sharon
    Marshall, Tracey
    Landesman, Yosef
    Kauffman, Michael
    Rebello, Sasha
    Mirza, Mansoor Slide Raza
    Schwartz, Gary K.
    Razak, Albiruni R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with heavily pretreated non-Hodgkin lymphoma (NHL).
    Gutierrez, Martin
    Goy, Andre
    Byrd, John C.
    Flynn, Joseph M.
    Sorensen, Morten
    Brown, Peter
    Gabrail, Nashat Y.
    Savona, Michael
    Flinn, Ian
    Baz, Rachid C.
    Shah, Bijal D.
    Stone, Richard M.
    Jacobsen, Eric
    Kukreti, Vishal
    Tiedemann, Roger E.
    Rashal, Tami
    Mirza, Mansoor Raza
    Shacham, Sharon
    Kauffman, Michael
    Kuruvilla, John
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma
    Cornell, R. Frank
    Rossi, Adriana C.
    Baz, Rachid
    Hofmeister, Craig C.
    Shustik, Chaim
    Richter, Joshua R.
    Chen, Christine
    Vogl, Dan T.
    Shacham, Sharon
    Baloglu, Erkan
    Senapedis, William
    Ellis, Joel
    Friedlander, Sharon
    Choe-Juliak, Cassandra
    Cubitt, Christopher L.
    Turner, Joel G.
    Sullivan, Daniel
    Kauffman, Michael
    BLOOD, 2016, 128 (22)
  • [24] A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of unclear export (SINE) in patients (pis) with advanced solid tumors
    Mau-Soerensen, Morten
    Razak, Albiruni R. A.
    Shields, Anthony Frank
    Gabrall, Nashat Y.
    Gereeltano, John F.
    Shacham, Sharon
    Lassen, Ulrlk Niels
    Rashal, Taml
    Cooksoy, Jennifer
    Landosman, Yosof
    Pond, Gregory
    Oza, Amit M.
    Kauffman, Michael
    Siu, Lillian L.
    Bedard, Philippe L.
    Mahaseth, Hemchandra
    Mlrza, Mansoor Raza
    Mahipal, Arnit
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINE) exportin I (XPOI) antagonist KPT-330 (Selinexor) in patients (pts) with platinum-resistant/refractory ovarian cancer (OvCa).
    Martignetti, John
    Razak, Albiruni R. A.
    Chen, Ying
    Gabrail, Nashat Y.
    Gerecitano, John F.
    Camacho, Catalina
    Pereira, Elena
    Dottino, Peter Remsen
    Shacham, Sharon
    McCauley, Dilara
    Rashal, Tami
    Saint-Martin, Jean-Richard
    Shacham, Eran
    Vincett, Darcy
    Kauffman, Michael
    Mirza, Mansoor Raza
    Sorensen, Morten
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] PRECLINICAL AND EARLY CLINICAL ACTIVITY OF THE ORAL SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) EXPORTIN 1 (XPO1) ANTAGONIST SELINEXOR (KPT-330) IN PATIENTS (PTS) WITH PLATINUM RESISTANT/REFRACTORY OVARIAN CANCER (OVCA)
    Martignetti, J.
    Razak, A. R. A.
    Chen, Y.
    Gabrail, N. Y.
    Gericitano, J. F.
    Camacho, C.
    Pereira, E.
    Evans, B.
    Dottino, P.
    McCauley, D.
    Shacham, S.
    Rashal, T.
    Saint-Martin, J.
    Shacham, E.
    Vincent, D.
    Kauffman, M.
    Mirza, M. R.
    Mau-Sorensen, M.
    ANNALS OF ONCOLOGY, 2014, 25
  • [27] Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Of a First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin's Lyphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
    Kuruvilla, John
    Gutierrez, Martin
    Shah, Bijal D.
    Gabrail, Nashat Y.
    Brown, Peter de Nully
    Stone, Richard M.
    Garzon, Ramiro
    Savona, Michael
    Siegel, David S.
    Baz, Rachid
    Mau-Sorensen, Morten
    Davids, Matthew S.
    Byrd, John C.
    Shacham, Sharon
    Rashal, Tami
    Yau, Cindy Y. F.
    McCauley, Dilara
    Saint-Martin, Jean-Richard
    McCartney, John
    Landesman, Yosef
    Klebanov, Boris
    Pond, Greg
    Oza, Amit M.
    Kauffman, Michael
    Mirza, Mansoor R.
    BLOOD, 2013, 122 (21)
  • [28] TOPICAL SELINEXOR (KPT-330), A SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) SHOWS INCREASED BLOOD FLOW AND ACCELERATED HEALING USING NONINVASIVE TECHNIQUES IN AN ISCHEMIC MODEL OF WOUND HEALING
    Ganesh, K.
    Kitsos, C.
    Rashal, T.
    Roy, S.
    Gnyawali, S.
    Friedlander, S.
    Chen, W.
    Ellis, J.
    Austad, B.
    McCauley, D.
    Kauffman, M.
    Shacham, S.
    Sen, C.
    WOUND REPAIR AND REGENERATION, 2015, 23 (02) : A22 - A22
  • [29] THE ORAL SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) SELINEXOR (KPT-330) ACTIVITY IN DOUBLE HIT DIFFUSE LARGE B CELL LYMPHOMAS (DLBCL) IN PRECLINICAL MODELS & CLINICAL ACTIVITY IN PATIENTS WITH DLBCL
    Kuruvilla, J.
    Cerchietti, L.
    Wagner-Johnston, N.
    Stone, R.
    Jacobsen, E.
    Mau-Sorensen, M.
    Brown, P.
    Baz, R.
    Shal, B.
    Flynn, J.
    Flinn, I.
    Kukreti, V.
    Tiedemann, R.
    Goy, A.
    Landesman, Y.
    Klebanov, B.
    Shacham, E.
    Saint-Martin, J. R.
    Marshall, T.
    McCartney, J.
    McCauley, D.
    Carlson, R.
    Rebello, S.
    Rashal, T.
    Mirza, M. R.
    Shacham, S.
    Kauffman, M.
    Gutierrez, M.
    HAEMATOLOGICA, 2014, 99 : 152 - 152
  • [30] Nuclear export inhibitor selinexor (KPT-330) demonstrates anti-tumor efficacy alone and in combination with chemotherapy in multiple breast cancer models
    Arango, Natalia Paez
    Evans, Kurt
    Zhao, Ming
    Yuca, Erkan
    Scott, Stephen
    Kim, Charissa
    Naing, Aung
    Meric-Bernstam, Funda
    CANCER RESEARCH, 2016, 76
12345